Search All Tech Briefings

Search technology briefings produced by NIHR Innovation Observatory. These are short reports on new or repurposed medicines that we have already sent to our stakeholders. Only those technologies (medicines) that are within the scope of our stakeholders will have a technology briefing available. Search our technology briefings by intervention (drug or device), specific indication (disease or condition), or general therapeutic area.

| 1184 Results

Clear All Filters

Title	Intervention	Indication	Therapeutic Area	Year	Actions
Mosunetuzumab for relapsed or refractory B-cell follicular lymphoma – third-line and greater	Mosunetuzumab (BTCT4465A)	Follicular lymphoma	Haematological Cancer and Lymphomas	2021	View \| Download
Mosunetuzumab (subcutaneous injection) for treating relapsed or refractory follicular lymphoma	Mosunetuzumab (BTCT4465A)	Follicular lymphoma	Haematological Cancer and Lymphomas	2024	View \| Download
Momelotinib for the treatment of symptomatic and anaemic myelofibrosis	Momelotinib	Anaemic myelofibrosis	Haematological Cancer and Lymphomas , Haematology	2022	View \| Download
Mobocertinib for locally advanced or metastatic NSCLC	TAK-788 (AP32788; Mobocertinib)	Non-small-cell lung cancer (NSCLC)	Lung and Respiratory Cancer	2021	View \| Download
Mitapivat for treating pyruvate kinase deficiency	Mitapivat (AG-348)	Pyruvate kinase deficiency	Endocrine Nutritional and Metabolic Disorders	2020	View \| Download
Mirvetuximab Soravtansine for Platinum-resistant Ovarian Cancer	Mirvetuximab soravtansine (IMGN853)	Epithelial ovarian cancer , Fallopian tube cancer , primary peritoneal cancer	Female Reproductive Cancer	2018	View \| Download
Mirvetuximab soravtansine for advanced, epithelial ovarian, fallopian tube, or primary peritoneal cancer with high folate receptor-alpha expression	Mirvetuximab soravtansine (IMGN853)	Epithelial ovarian cancer , Fallopian tube cancer , primary peritoneal cancer	Female Reproductive Cancer	2023	View \| Download
Mirikizumab for treating moderately to severely active Crohn’s disease	Mirikizumab (LY3074828)	Crohn's disease	Gastroenterology , Immunology	2022	View \| Download
Mirikizumab for the treatment of moderately to severely active ulcerative colitis	Mirikizumab (LY3074828)	Ulcerative colitis	Gastroenterology	2021	View \| Download
Mirabegron for neurogenic detrusor overactivity in people aged 3 to 17 years	Mirabegron	Neurogenic detrusor overactivity	Neurology , Urology	2022	View \| Download